Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma

Pediatric Blood and Cancer

Volumn 52, Issue 4, 2009, Pages 476-480

  Peyrl, Andreas ^a   Azizi, Amedeo ^a   Czech, Thomas ^a   Gruber Olipitz, Mariella ^a   Jones, Neil ^b   Haberler, Christine ^c   Prayer, Daniela ^a   Autzinger, Eva ^a   Slavc, Irene ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Children; CNS tumor; Imatinib; Progressive hypothalamic chiasmatic glioma

Indexed keywords

ARGININE; CARBOPLATIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; DRUG WITHDRAWAL; ENDOTHELIUM CELL; FEMALE; GLIOMA; HUMAN; HUMAN CELL; HYPOTHALAMIC CHIASMATIC GLIOMA; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PARALYTIC ILEUS; PERIPHERAL EDEMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT RESPONSE; TREMOR; CLINICAL TRIAL; DRUG EFFECT; HYPOTHALAMUS TUMOR; OPTIC CHIASM; OPTIC NERVE GLIOMA; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; HYPOTHALAMIC NEOPLASMS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; OPTIC CHIASM; OPTIC NERVE GLIOMA; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 62449240870     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21881     Document Type: Article

References (21)

1. Laithier V, Grill J, Le Deley MC, et al. Progression-free survival in children with optic pathway tumors: Dependence on age and the quality of the response to chemotherapy-Results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 2003;21:4572-4578.
2. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low- grade gliomas. J Neurosurg 1997;86:747-754.
3. Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002;20:4209-4216.
4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myeloge-nous leukemia. N Engl J Med 2002;346:645-652.
5. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002;99:1928-1937.
6. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002;99:3530-3539.
7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
8. McLaughlin ME, Robson CD, Kieran MW, et al. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): A case report and laboratory investigation. Pediatr Hematol Oncol 2003;25:644-648.
9. Scheithauer BW, Hawkins C, Tihan T, et al. Pilocytic astrocytoma. In: Lois DN, Ohgaki H, Wiestler O, Cavanee WK, editors. WHO classification of tumours of the central nervous system, 4th edition.
10. Lyon: IARC; 2007. pp. 14-21.
11. Haberler C, Gelpi E, Marosi C, et al. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: Possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 2006;76:105-109.
12. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
13. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-5783.
14. Hagerstrand D, Hesselager G, Achterberg S, et al. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 2006;25:4913-4922.
15. Raymond E, Brandes AA, Dittrich C, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008;26:4659-4665.
16. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916.
17. Champagne MA, Capdeville R, Krailo M, et al. Children's Oncology Group phase 1 study. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-2660.
18. Millot F, GuilhotJ, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-192.
19. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report. Neuro Oncol 2007;9:145-160.
20. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-1203.
21. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-581.